Yuhan (000100.KS) Q1 2026: Net Profit +134% on Non-Op Windfall
*Equity method gains and financial income power the headline profit surge; lazertinib advances to five-market approval while core operating margins hold at 1.7%*
Source: Quarterly Report (104th Fiscal Year, Q1) — Filed April 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“Yuhan (000100.KS) Q1 2026: Net Profit +134% on Non-Op Windfall”
This article became available on June 15, 2026. Subscribe to read in full, or wait until September 13, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
You just read what happened. Here's how to read what it means.
We read Yuhan's latest DART filing in full — financials under K-IFRS, governance, and what it means for the stock. PDF in your inbox in 30–40 min.
$12 · one-time
Get the Yuhan reportReading several Korean stocks a week? Get on-demand analysis on any KOSPI or KOSDAQ company, whenever you need it.
$9.99 · monthly
SubscribeIndependent journalism based on primary DART filings — not investment advice. No brokerage affiliation.
